186 related articles for article (PubMed ID: 31359041)
21. Viral mimetic priming enhances α-synuclein-induced degeneration: Implications for Parkinson's disease.
Olsen LK; Cairns AG; Ådén J; Moriarty N; Cabre S; Alamilla VR; Almqvist F; Dowd E; McKernan DP
Brain Behav Immun; 2019 Aug; 80():525-535. PubMed ID: 31029796
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
23. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.
Reynolds AD; Glanzer JG; Kadiu I; Ricardo-Dukelow M; Chaudhuri A; Ciborowski P; Cerny R; Gelman B; Thomas MP; Mosley RL; Gendelman HE
J Neurochem; 2008 Mar; 104(6):1504-25. PubMed ID: 18036154
[TBL] [Abstract][Full Text] [Related]
24. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
Galiano-Landeira J; Torra A; Vila M; Bové J
Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
[TBL] [Abstract][Full Text] [Related]
25. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
26. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
[TBL] [Abstract][Full Text] [Related]
27. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
Zhang QS; Heng Y; Yuan YH; Chen NH
Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
[TBL] [Abstract][Full Text] [Related]
28. A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging.
Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Mišić B; Dagher A
Neuroimage; 2019 Apr; 190():69-78. PubMed ID: 29277406
[TBL] [Abstract][Full Text] [Related]
29. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
[TBL] [Abstract][Full Text] [Related]
30. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
31. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
[TBL] [Abstract][Full Text] [Related]
32. Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study.
Zhang Y; Wu IW; Tosun D; Foster E; Schuff N;
PLoS One; 2016; 11(10):e0165540. PubMed ID: 27798653
[TBL] [Abstract][Full Text] [Related]
33. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
[TBL] [Abstract][Full Text] [Related]
34. Transcriptomic signatures of brain regional vulnerability to Parkinson's disease.
Keo A; Mahfouz A; Ingrassia AMT; Meneboo JP; Villenet C; Mutez E; Comptdaer T; Lelieveldt BPF; Figeac M; Chartier-Harlin MC; van de Berg WDJ; van Hilten JJ; Reinders MJT
Commun Biol; 2020 Mar; 3(1):101. PubMed ID: 32139796
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
36. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.
Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T
Front Immunol; 2021; 12():719807. PubMed ID: 34691027
[TBL] [Abstract][Full Text] [Related]
37. Heredity in Parkinson's disease: new findings.
Lev N; Melamed E
Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
[TBL] [Abstract][Full Text] [Related]
38. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
39. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
[TBL] [Abstract][Full Text] [Related]
40. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease.
Neystat M; Lynch T; Przedborski S; Kholodilov N; Rzhetskaya M; Burke RE
Mov Disord; 1999 May; 14(3):417-22. PubMed ID: 10348463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
